EMBLAVEO

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Feb 07, 2025

   1 yr 5 mo ago

2. Patent 7112592 expires

   Listed drug substance patent expiration.

   Jan 07, 2026

   5 mo ago

3. Today

4. Patent 7612087 expires

   Listed drug product patent expiration.

   Nov 12, 2026

   in 5 mo

5. Exclusivity ends · NP

   New product exclusivity (3 years)

   Feb 07, 2028

   in 1 yr 8 mo

6. Patent 8835455 expires

   Listed drug product patent expiration.

   Oct 08, 2030

   in 4 yr 4 mo

7. Patent 8471025 expires

   Listed drug substance patent expiration.

   Aug 12, 2031

   in 5 yr 3 mo

8. Patent 8969566 expires

   Listed drug substance patent expiration.

   Jun 15, 2032

   in 6 yr 1 mo

9. Patent 9284314 expires

   Listed drug substance patent expiration.

   Jun 15, 2032

   in 6 yr 1 mo

10. Patent 9695122 expires

    Listed drug substance patent expiration.

    Jun 15, 2032

    in 6 yr 1 mo

11. Exclusivity ends · GAIN

    Qualified infectious disease product exclusivity (adds 5 years)

    Feb 07, 2033

    in 6 yr 9 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

• NPNew product exclusivity (3 years)

  Feb 07, 2028

  in 1 yr 8 mo

• GAINQualified infectious disease product exclusivity (adds 5 years)

  Feb 07, 2033

  in 6 yr 9 mo

Listed patents (7)